Patients with secondary AML are eligible for enrollment onto the trial; secondary AML is defined as AML that has developed in a person with a history of antecedent blood count abnormalities, or myelodysplastic syndrome (MDS), or a myeloproliferative disorder (excluding chronic myeloid leukemia); or a history of prior chemotherapy or radiation therapy for a disease other than AML* NOTE: Prior therapy of MDS with decitabine, low-dose cytarabine, or azacitidine is excludedXx_NEWLINE_xXThe following malignancies will be considered eligible if progressive or persistent:* Chronic lymphocytic leukemia (CLL)* Non-Hodgkin lymphoma (NHL)* Hodgkin lymphoma (HL)* Multiple myeloma (MM)* Acute leukemia (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL])* Myelodysplastic syndrome (MDS)* Myeloproliferative neoplasms (MPN)* Chronic myeloid leukemia (CML)Xx_NEWLINE_xXPatients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AMLXx_NEWLINE_xXPatients must have one of the following, histologically or cytologically confirmed:* Acute myeloid leukemia (AML) [non- acute promyelocytic leukemia (APL) AML]** If previously treated:*** AML that is relapsed or refractory to at least one prior line of therapy** If previously untreated, must meet all of the following:*** >= 60 years of age*** Secondary or therapy-related AML*** Does NOT bear favorable cytogenetic and/or molecular features, eg, core-binding factor abnormalities, FLT3 Internal Tandem Duplication (FLT3-ITD) negative/NPM1 mutated, biallelic CCAAT/enhancer binding protein alpha (CEBPA) mutation without FLT3-ITD* Chronic myeloid leukemia blast crisis (CML-BC)** Relapsed or refractory to at least one Bcr-Abl-TKI-containing regimen* Myelodysplastic syndrome (MDS), must meet all of the following:** Higher risk MDS [intermediate-2 or high risk by the original International Prognostic Scoring System (IPSS)]** Relapsed, refractory, or intolerant to at least one prior line of therapy containing hypomethylating agents (deoxyribonucleic acid [DNA] methyltransferase inhibitors)Xx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXEvidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated* No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)Xx_NEWLINE_xXPatients may not have features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicatedXx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smearXx_NEWLINE_xXPatients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), or features suggestive of MDS/AMLXx_NEWLINE_xXNo features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) on peripheral blood smearXx_NEWLINE_xXPatients with a history of myelodysplastic syndrome (MDS)Xx_NEWLINE_xXParticipants with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)Xx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukemiaXx_NEWLINE_xX